Terms: = Leukemia AND ASXL1, ENSG00000171456, 171023, Q8IXJ9, MGC71111, MGC117280, KIAA0978 AND Clinical Outcome
23 results:
1. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Ozga M; Nicolet D; Mrózek K; Yilmaz AS; Kohlschmidt J; Larkin KT; Blachly JS; Oakes CC; Buss J; Walker CJ; Orwick S; Jurinovic V; Rothenberg-Thurley M; Dufour A; Schneider S; Sauerland MC; Görlich D; Krug U; Berdel WE; Woermann BJ; Hiddemann W; Braess J; Subklewe M; Spiekermann K; Carroll AJ; Blum WG; Powell BL; Kolitz JE; Moore JO; Mayer RJ; Larson RA; Uy GL; Stock W; Metzeler KH; Grimes HL; Byrd JC; Salomonis N; Herold T; Mims AS; Eisfeld AK
Leukemia; 2024 Jan; 38(1):45-57. PubMed ID: 38017103
[TBL] [Abstract] [Full Text] [Related]
2. Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes.
Konishi T; Sadato D; Toya T; Hirama C; Kishida Y; Nagata A; Yamada Y; Shingai N; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Okuyama Y; Harada H; Ohashi K; Harada Y; Doki N
Sci Rep; 2023 Feb; 13(1):2641. PubMed ID: 36788335
[TBL] [Abstract] [Full Text] [Related]
3. PCR-Fluo-asxl1-FA: A fast, sensitive and inexpensive complementary method to detect asxl1 mutations in haematological malignancies.
Friedrich C; Zalmaï L; Gay J; Coude MM; Bravetti C; Vazquez R; Temple M; Duroyon E; Darnige L; Decroocq J; Alary AS; Kosmider O
Int J Lab Hematol; 2022 Oct; 44(5):928-933. PubMed ID: 35793805
[TBL] [Abstract] [Full Text] [Related]
4. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification.
van der Werf I; Wojtuszkiewicz A; Meggendorfer M; Hutter S; Baer C; Heymans M; Valk PJM; Kern W; Haferlach C; Janssen JJWM; Ossenkoppele GJ; Cloos J; Haferlach T
Blood Adv; 2021 Sep; 5(17):3254-3265. PubMed ID: 34448812
[TBL] [Abstract] [Full Text] [Related]
5. clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.
Tsai CH; Tang JL; Tien FM; Kuo YY; Wu DC; Lin CC; Tseng MH; Peng YL; Hou MF; Chuang YK; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
Blood Adv; 2021 May; 5(10):2456-2466. PubMed ID: 33999144
[TBL] [Abstract] [Full Text] [Related]
6. Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia.
Wang B; Guan W; Lv N; Li T; Yu F; Huang Y; Wang Y; Li L; Yu L
Hematology; 2021 Dec; 26(1):371-379. PubMed ID: 33971800
[TBL] [Abstract] [Full Text] [Related]
7. Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome.
Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Guo R; Tierens A; Minden MD; Chang H
Hum Pathol; 2020 Oct; 104():117-126. PubMed ID: 32798550
[TBL] [Abstract] [Full Text] [Related]
8. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
[TBL] [Abstract] [Full Text] [Related]
9. Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.
Follo MY; Pellagatti A; Armstrong RN; Ratti S; Mongiorgi S; De Fanti S; Bochicchio MT; Russo D; Gobbi M; Miglino M; Parisi S; Martinelli G; Cavo M; Luiselli D; McCubrey JA; Suh PG; Manzoli L; Boultwood J; Finelli C; Cocco L
Leukemia; 2019 Sep; 33(9):2276-2290. PubMed ID: 30787430
[TBL] [Abstract] [Full Text] [Related]
10. clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation.
Grimm J; Bill M; Jentzsch M; Beinicke S; Häntschel J; Goldmann K; Schulz J; Cross M; Franke GN; Behre G; Vucinic V; Pönisch W; Lange T; Niederwieser D; Schwind S
Bone Marrow Transplant; 2019 Aug; 54(8):1189-1197. PubMed ID: 30504903
[TBL] [Abstract] [Full Text] [Related]
11. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.
Naumann N; Jawhar M; Schwaab J; Kluger S; Lübke J; Metzgeroth G; Popp HD; Khaled N; Horny HP; Sotlar K; Valent P; Haferlach C; Göhring G; Schlegelberger B; Meggendorfer M; Hofmann WK; Cross NCP; Reiter A; Fabarius A
Genes Chromosomes Cancer; 2018 May; 57(5):252-259. PubMed ID: 29341334
[TBL] [Abstract] [Full Text] [Related]
12. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
Elena C; Gallì A; Such E; Meggendorfer M; Germing U; Rizzo E; Cervera J; Molteni E; Fasan A; Schuler E; Ambaglio I; Lopez-Pavia M; Zibellini S; Kuendgen A; Travaglino E; Sancho-Tello R; Catricalà S; Vicente AI; Haferlach T; Haferlach C; Sanz GF; Malcovati L; Cazzola M
Blood; 2016 Sep; 128(10):1408-17. PubMed ID: 27385790
[TBL] [Abstract] [Full Text] [Related]
13. Clonal hematopoiesis in acquired aplastic anemia.
Ogawa S
Blood; 2016 Jul; 128(3):337-47. PubMed ID: 27121470
[TBL] [Abstract] [Full Text] [Related]
14. asxl1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
Valletta S; Dolatshad H; Bartenstein M; Yip BH; Bello E; Gordon S; Yu Y; Shaw J; Roy S; Scifo L; Schuh A; Pellagatti A; Fulga TA; Verma A; Boultwood J
Oncotarget; 2015 Dec; 6(42):44061-71. PubMed ID: 26623729
[TBL] [Abstract] [Full Text] [Related]
15. clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.
Renneville A; Abdelali RB; Chevret S; Nibourel O; Cheok M; Pautas C; Duléry R; Boyer T; Cayuela JM; Hayette S; Raffoux E; Farhat H; Boissel N; Terre C; Dombret H; Castaigne S; Preudhomme C
Oncotarget; 2014 Feb; 5(4):916-32. PubMed ID: 24659740
[TBL] [Abstract] [Full Text] [Related]
16. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
[TBL] [Abstract] [Full Text] [Related]
17. [Research on molecular markers for epigenetic changes in myeloid malignancies].
Li L; Sun XM
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Dec; 30(6):687-92. PubMed ID: 24327148
[TBL] [Abstract] [Full Text] [Related]
18. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia.
Hou HA; Lin CC; Chou WC; Liu CY; Chen CY; Tang JL; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Kuo YY; Lee MC; Liu MC; Liu CW; Lin LI; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Leukemia; 2014 Jan; 28(1):50-8. PubMed ID: 23929217
[TBL] [Abstract] [Full Text] [Related]
19. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
[TBL] [Abstract] [Full Text] [Related]
20. Mutations in asxl1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
Gelsi-Boyer V; Brecqueville M; Devillier R; Murati A; Mozziconacci MJ; Birnbaum D
J Hematol Oncol; 2012 Mar; 5():12. PubMed ID: 22436456
[TBL] [Abstract] [Full Text] [Related]
[Next]
